These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 39075994)

  • 21. Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study.
    Mancuso ME; Mahlangu J; Sidonio R; Trask P; Uguen M; Chang T; Shima M; Young G; Oldenburg J; von Mackensen S
    Haemophilia; 2020 Nov; 26(6):1009-1018. PubMed ID: 33084175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generic and disease-specific quality of life among youth and young men with Hemophilia in Canada.
    St-Louis J; Urajnik DJ; Ménard F; Cloutier S; Klaassen RJ; Ritchie B; Rivard GE; Warner M; Blanchette V; Young NL
    BMC Hematol; 2016; 16():13. PubMed ID: 27158500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A.
    García-Dasí M; Aznar JA; Jiménez-Yuste V; Altisent C; Bonanad S; Mingot E; Lucía F; Giménez F; López MF; Marco P; Pérez R; Fernández MÁ; Paloma MJ; Galmes B; Herrero S; García-Talavera JA
    Haemophilia; 2015 Jul; 21(4):458-64. PubMed ID: 25649244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1.
    O'Mahony B; Dunn AL; Leavitt AD; Peyvandi F; Ozelo MC; Mahlangu J; Peerlinck K; Wang JD; Lowe GC; Tan CW; Giermasz A; Tran H; Khoo TL; Cockrell E; Pepperell D; Chambost H; López Fernández MF; Kazmi R; Majerus E; Skinner MW; Klamroth R; Quinn J; Yu H; Wong WY; Robinson TM; Pipe SW
    J Thromb Haemost; 2023 Dec; 21(12):3450-3462. PubMed ID: 37678546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe haemophilia A children on low-dose tertiary prophylaxis showed less joint deterioration and better maintenance of functional independence than children on on-demand treatment: A 6-year follow-up study.
    Liu Y; Chen L; Li K; Shi M; Poon MC
    Haemophilia; 2020 Sep; 26(5):779-785. PubMed ID: 32700412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emicizumab Prophylaxis in Patients with Severe Hemophilia A: Insights from A Resource Limited Country.
    Borhany M; Arshad A; Qureshi H; Nadeem R; Jamal A; Ahmed Khan R
    Clin Appl Thromb Hemost; 2024; 30():10760296231224357. PubMed ID: 38166474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health-related quality of life of moderate and severe haemophilia patients: Results of the haemophilia-specific quality of life index in Korea.
    Baek HJ; Park YS; Yoo KY; Cha JH; Kim YJ; Lee KS
    PLoS One; 2020; 15(9):e0238686. PubMed ID: 32881977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.
    Skinner MW; Négrier C; Paz-Priel I; Chebon S; Jiménez-Yuste V; Callaghan MU; Lehle M; Niggli M; Mahlangu J; Shapiro A; Shima M; Campinha-Bacote A; Levy GG; Oldenburg J; von Mackensen S; Pipe SW
    Haemophilia; 2021 Sep; 27(5):854-865. PubMed ID: 34171159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires.
    Astermark J; Hermans C; Ezzalfani M; Aballéa S; Santagostino E; Hakimi Z; Nazir J
    Haemophilia; 2022 Jan; 28(1):18-26. PubMed ID: 34761474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determinants of Quality of Life in Children and Adolescents With Hemophilia in Kabul, Afghanistan: First Report.
    Mousavi SH; Dayer MS; Pourhaji F; Delshad MH; Mesbah-Namin SA
    Arch Iran Med; 2019 Jul; 22(7):384-389. PubMed ID: 31679381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).
    Mahlangu J; Oldenburg J; Callaghan MU; Shima M; Mancuso ME; Trask P; Recht M; Garcia C; Yang R; Lehle M; Macharia H; Asikanius E; Levy GG; Kruse-Jarres R; von Mackensen S
    Haemophilia; 2019 May; 25(3):382-391. PubMed ID: 31016855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII.
    Kearney S; Raffini LJ; Pham TP; Lee XY; von Mackensen S; Landorph A; Takedani H; Oldenburg J
    Patient Prefer Adherence; 2019; 13():497-513. PubMed ID: 31040652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pilot study of once-a-day prophylaxis for youth and young adults with severe haemophilia A.
    Crivianu-Gaita V; Rivard GE; Carcao M; Teitel J; St-Louis J; Blanchette V; Pullenayegum E; Abad A; Feldman BM
    Haemophilia; 2016 Sep; 22(5):e401-5. PubMed ID: 27481574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Breakthrough bleeding in adult patients with severe hemophilia A receiving low- and intermediate-dose FVIII for tertiary prophylaxis: characteristics and influencing factors].
    Qiu SQ; Zhuang JM; Zhou X; Yin RX; Liu ZQ; Ma F; Li YJ; Sun J
    Nan Fang Yi Ke Da Xue Xue Bao; 2017 Oct; 37(10):1391-1395. PubMed ID: 29070472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients With Severe Hemophilia A: A Retrospective Analysis From the ReCARE Study.
    Yao W; Xiao J; Cheng X; Feng G; Li C; Zhang X; Hu Q; Xu W; Sun J; Yang R; Li X; Zhou R; Lian S; Gu J; Wu J; Zhao Y; Wu R
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):851-858. PubMed ID: 27920236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment regimens, patient reported outcomes and health-related quality of life in children with moderate and severe hemophilia A in China: using real-world data.
    Zhang L; Zhang P; Chen W
    Orphanet J Rare Dis; 2023 Aug; 18(1):232. PubMed ID: 37542281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tailored prophylaxis in children with severe hemophilia: A four-year Iranian study.
    Baghaipour M; Salimi T; Bahoush G; Jazebi M; Ala F; Azizi Saraji A; Dorgalaleh A; Moazezi Nekoei Asl SS; Mohamadamini M; Tabibian S
    Transfus Apher Sci; 2021 Dec; 60(6):103212. PubMed ID: 34257016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-dose tertiary prophylactic therapy reduces total number of bleeds and improves the ability to perform activities of daily living in adults with severe haemophilia A: a single-centre experience from Beijing.
    Hua B; Lian X; Li K; Lee A; Poon MC; Zhao Y
    Blood Coagul Fibrinolysis; 2016 Mar; 27(2):136-40. PubMed ID: 26258677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health-related quality of life in Egyptian children and adolescents with hemophilia A.
    Tantawy AA; Mackensen SV; El-Laboudy MA; Labib JH; Moftah F; El-Telbany MA; Mansour WA
    Pediatr Hematol Oncol; 2011 Apr; 28(3):222-9. PubMed ID: 21271776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective study of health-related quality of life of boys with severe haemophilia A in China: comparing on-demand to prophylaxis treatment.
    Wu R; Sun J; Xiao J; Liu Y; Xue F; Wang H; Tang L; Zhao Y; Li K; Yang R; Hu Y; Luke KH; Poon MC; Blanchette VS; Usuba K; Young NL
    Haemophilia; 2017 May; 23(3):430-436. PubMed ID: 28345299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.